1
|
Ragulan C, Ikami Y, Desai K, Varun Lawrence P, Mohammed Musheer Aalam S, Kannan N, Sadanandam A. 218P A symbiotic relationship between persistent and emerging resistant oligo-clones dictates resistance to immunotherapy in pancreatic cancer. Immuno-Oncology and Technology 2022. [DOI: 10.1016/j.iotech.2022.100329] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/14/2022]
|
2
|
Herpels M, Mansurov A, Ragulan C, Hussain A, Ishihara J, Sadanandam A. 37P Synthetic tumour-infiltrating interleukin (IL)-12 for targeted and tolerable immunotherapy reduces metastasis in pancreatic cancer. Immuno-Oncology and Technology 2022. [DOI: 10.1016/j.iotech.2022.100142] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
|
3
|
Hussain A, Sadanandam A. 5MO Prognostic intra-tumoural heterogeneity in cancer-associated fibroblasts (CAFs) is linked to evolution of tumour from normal in pancreatic cancer. Ann Oncol 2021. [DOI: 10.1016/j.annonc.2021.08.2001] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022] Open
|
4
|
Angerilli V, Fontana E, Lonardi S, Sbaraglia M, Borelli B, Munari G, Salmaso R, Guzzardo V, Spolverato G, Pucciarelli S, Pilati P, Hahne JC, Bergamo F, Zagonel V, Dei Tos AP, Sadanandam A, Loupakis F, Valeri N, Fassan M. Intratumor morphologic and transcriptomic heterogeneity in V600EBRAF-mutated metastatic colorectal adenocarcinomas. ESMO Open 2021; 6:100211. [PMID: 34271310 PMCID: PMC8282957 DOI: 10.1016/j.esmoop.2021.100211] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/12/2021] [Revised: 06/23/2021] [Accepted: 06/25/2021] [Indexed: 11/29/2022] Open
Abstract
BACKGROUND Intratumor heterogeneity (ITH) is described as the presence of various clones within one tumor, each with their own unique features in terms of morphology, inflammation, genetics or transcriptomics. Heterogeneity provides the fuel for drug resistance; therefore, an accurate assessment of tumor heterogeneity is essential for the development of effective therapies. The purpose of this study was to dissect morphologic and molecular ITH in colorectal adenocarcinoma. MATERIALS AND METHODS A series of 120 V600EBRAF-mutated (V600EBRAFmt) consecutive metastatic colorectal adenocarcinomas was assessed for morphologic heterogeneity. The two heterogeneous components of each specimen underwent a histopathological, immunohistochemical and molecular characterization to evaluate: histologic variant, grading, tumor-infiltrating lymphocytes (TILs), mismatch repair proteins' expression, KRAS/BRAF/NRAS mutations, microsatellite instability (MSI) status and consensus molecular subtype (CMS). RESULTS Thirty-one out of 120 (25.8%) V600EBRAFmt primary colorectal adenocarcinomas presented a heterogeneous morphology. Among these, eight cases had adequate material for molecular profiling. Five out of the eight (62.5%) cases resulted instable at MSI testing. The majority (62.5%) of the samples showed a CMS4 phenotype based on gene expression profiling. Heterogeneity in CMS classification was observed in four out of eight cases. One out of eight cases presented significant heterogeneity in the number of TILs between the two components of the tumor. CONCLUSIONS Although the distribution of the immune infiltrate appears relatively conserved among heterogeneous areas of the same tumor, changes in gene expression profile and CMS occur in 50% of V600EBRAFmt adenocarcinoma cases in our small series and might contribute to variability in response to anticancer therapy and clinical outcomes. Assessment of morphological and molecular ITH is needed to improve colorectal cancer classification and to tailor anticancer treatments and should be included in the pathology report.
Collapse
Affiliation(s)
- V Angerilli
- Department of Medicine (DIMED), Surgical Pathology Unit, University of Padua, Padua, Italy
| | - E Fontana
- Division of Molecular Pathology, Institute of Cancer Research, London, UK
| | - S Lonardi
- Medical Oncology Unit 3, Department of Oncology, Veneto Institute of Oncology IOV-IRCCS, Castelfranco Veneto, Italy
| | - M Sbaraglia
- Department of Medicine (DIMED), Surgical Pathology Unit, University of Padua, Padua, Italy
| | - B Borelli
- Department of Translational Research and New Technologies in Medicine and Surgery, Unit of Medical Oncology, Azienda Ospedaliero-Universitaria Pisana, University of Pisa, Pisa, Italy
| | - G Munari
- Veneto Institute of Oncology IOV-IRCCS, Padua, Italy
| | - R Salmaso
- Department of Medicine (DIMED), Surgical Pathology Unit, University of Padua, Padua, Italy
| | - V Guzzardo
- Department of Medicine (DIMED), Surgical Pathology Unit, University of Padua, Padua, Italy
| | - G Spolverato
- Department of Surgery, Oncology & Gastroenterology, 1st Surgery Unit, University of Padua, Padua, Italy
| | - S Pucciarelli
- Department of Surgery, Oncology & Gastroenterology, 1st Surgery Unit, University of Padua, Padua, Italy
| | - P Pilati
- Surgery Unit, Veneto Institute of Oncology IOV-IRCCS, Castelfranco Veneto, Italy
| | - J C Hahne
- Division of Molecular Pathology, Institute of Cancer Research, London, UK
| | - F Bergamo
- Medical Oncology Unit 1, Department of Oncology, Veneto Institute of Oncology IOV-IRCCS, Padua, Italy
| | - V Zagonel
- Medical Oncology Unit 1, Department of Oncology, Veneto Institute of Oncology IOV-IRCCS, Padua, Italy
| | - A P Dei Tos
- Department of Medicine (DIMED), Surgical Pathology Unit, University of Padua, Padua, Italy
| | - A Sadanandam
- Division of Molecular Pathology, Institute of Cancer Research, London, UK
| | - F Loupakis
- Department of Surgery, Oncology & Gastroenterology, 1st Surgery Unit, University of Padua, Padua, Italy
| | - N Valeri
- Division of Molecular Pathology, Institute of Cancer Research, London, UK; Division of Surgery and Cancer, Imperial College London, London, UK
| | - M Fassan
- Department of Medicine (DIMED), Surgical Pathology Unit, University of Padua, Padua, Italy; Veneto Institute of Oncology IOV-IRCCS, Padua, Italy.
| |
Collapse
|
5
|
Tan M, Nyamundanda G, Fontana E, Hazell S, Ragulan C, Jones K, Abah B, Jacobs T, Bowes J, Sadanandam A, Huddart R. PO-1207: Exploring molecular subtype as a biomarker of radiation response in muscle-invasive bladder cancer. Radiother Oncol 2020. [DOI: 10.1016/s0167-8140(21)01225-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
6
|
Sodergren MH, Mangal N, Wasan H, Sadanandam A, Balachandran VP, Jiao LR, Habib N. Immunological combination treatment holds the key to improving survival in pancreatic cancer. J Cancer Res Clin Oncol 2020; 146:2897-2911. [PMID: 32748119 PMCID: PMC7519893 DOI: 10.1007/s00432-020-03332-5] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/14/2020] [Accepted: 07/22/2020] [Indexed: 12/18/2022]
Abstract
Advances in surgery, peri-operative care and systemic chemotherapy have not significantly improved the prognosis of pancreatic cancer for several decades. Early clinical trials of immunotherapy have yielded disappointing results proposing other means by which the tumour microenvironment serves to decrease the immune response. Additionally, the emergence of various subtypes of pancreatic cancer has emerged as a factor for treatment responses with immunogenic subtypes carrying a better prognosis. Herein we discuss the reasons for the poor response to checkpoint inhibitors and outline a rationale why combination treatments are likely to be most effective. We review the therapies which could provide optimal synergistic effects to immunotherapy including chemotherapy, agents targeting the stroma, co-stimulatory molecules, vaccinations and methods of immunogenic tumour priming including radiofrequency ablation. Finally, we discuss reasons why peri-operative and in particular neoadjuvant combination treatments are likely to be most effective and should be considered for early clinical trials.
Collapse
Affiliation(s)
- M H Sodergren
- Department of Surgery and Cancer, Imperial College London, Hammersmith Campus, DuCane Road, London, W12 0HS, UK.
| | - N Mangal
- Department of Surgery and Cancer, Imperial College London, Hammersmith Campus, DuCane Road, London, W12 0HS, UK
| | - H Wasan
- Department of Surgery and Cancer, Imperial College London, Hammersmith Campus, DuCane Road, London, W12 0HS, UK
| | - A Sadanandam
- Division of Molecular Pathology, Institute for Cancer Research, London, UK.,Centre for Molecular Pathology, Royal Marsden Hospital, London, UK
| | - V P Balachandran
- Hepatopancreatobiliary Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, USA.,Parker Institute for Cancer Immunotherapy, Memorial Sloan Kettering Cancer Center, New York, USA.,David M. Rubenstein Center for Pancreatic Cancer Research, Memorial Sloan Kettering Cancer Center, New York, USA
| | - L R Jiao
- Department of Surgery and Cancer, Imperial College London, Hammersmith Campus, DuCane Road, London, W12 0HS, UK
| | - N Habib
- Department of Surgery and Cancer, Imperial College London, Hammersmith Campus, DuCane Road, London, W12 0HS, UK
| |
Collapse
|
7
|
Affiliation(s)
- G Nyamundanda
- Division of Molecular Pathology, Institute of Cancer Research, London, UK
| | - E Fontana
- Division of Molecular Pathology, Institute of Cancer Research, London, UK
| | - A Sadanandam
- Division of Molecular Pathology, Institute of Cancer Research, London, UK.
| |
Collapse
|
8
|
Borelli B, Fontana E, Giordano M, Antoniotti C, Bergamo F, Murgioni S, Pietrantonio F, Morano F, Tamburini E, Boccaccino A, Santini D, Conca V, Pella N, Maiello E, Ugolini C, Fontanini G, Falcone A, Nyamundanda G, Sadanandam A, Cremolini C. SO-20 Consensus molecular subtypes and CRCAssigner classifications in metastatic colorectal cancer (mCRC): Prognostic and predictive impact in the TRIBE2 study. Ann Oncol 2020. [DOI: 10.1016/j.annonc.2020.04.035] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022] Open
|
9
|
Desai K, Ragulan C, Lawrence P, Wullschleger S, Tichet M, Box G, Fontana E, Young K, Larkin J, Hanahan D, Cunningham D, Starling N, Sadanandam A. A personalised approach for anti-GITR-based immunotherapy in pre-clinical models of pancreatic ductal adenocarcinoma. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz452.018] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
10
|
Fontana E, Nyamundanda G, Cunningham D, Jonker D, Siu L, Tu D, Sclafani F, Eason K, Ragulan C, Hulkki-Wilson S, Loree J, Giordano M, Lawrence P, Shapiro J, Cremolini C, Starling N, Pietrantonio F, Trusolino L, O’Callaghan C, Sadanandam A. Association between transit-amplifying signature and outcomes of patients treated with anti-epidermal growth factor receptor (EGFR) therapy in colorectal cancer. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz246.008] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
11
|
Sclafani F, Cascione L, Cunningham D, Young K, Carotenuto P, Fassan M, Salati M, Lanese A, Berenguer Pina J, Kouvelakis K, Vendrell I, Said-Huntingford I, Previdi M, Begum R, Gillbanks A, Hedayat S, Sadanandam A, Lampis A, Hahne J, Valeri N, Chau I, Braconi C. Identification of a nanostring signature that differentiates early pancreatic cancers according to stromal composition and predicts clinical outcome. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz156.002] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
12
|
Abstract
The Colorectal Cancer Subtyping Consortium identified four gene expression consensus molecular subtypes, CMS1 (immune), CMS2 (canonical), CMS3 (metabolic), and CMS4 (mesenchymal), using multiple microarray or RNA-sequencing datasets of primary tumor samples mainly from early stage colon cancer patients. Consequently, rectal tumors and stage IV tumors (possibly reflective of more aggressive disease) were underrepresented, and no chemo- and/or radiotherapy pretreated samples or metastatic lesions were included. In view of their possible effect on gene expression and consequently subtype classification, sample source and treatments received by the patients before collection must be carefully considered when applying the classifier to new datasets. Recently, several correlative analyses of clinical trials demonstrated the applicability of this classification to the metastatic setting, confirmed the prognostic value of CMS subtypes after relapse and hinted at differential sensitivity to treatments. Here, we discuss why contexts and equivocal factors need to be taken into account when analyzing clinical trial data, including potential selection biases, type of platform, and type of algorithm used for subtype prediction. This perspective article facilitates both our clinical and research understanding of the application of this classifier to expedite subtype-based clinical trials.
Collapse
Affiliation(s)
- E Fontana
- Division of Molecular Pathology, The Institute of Cancer Research, London; Centre for Molecular Pathology, The Royal Marsden NHS Foundation Trust, London, UK
| | - K Eason
- Division of Molecular Pathology, The Institute of Cancer Research, London
| | - A Cervantes
- CIBERONC, Department of Medical Oncology, Biomedical Research Institute INCLIVA, University of Valencia, Valencia
| | - R Salazar
- Institut Catala d'Oncologia, L'Institut d'Investigació Biomèdica de Bellvitge, Barcelona, Spain
| | - A Sadanandam
- Division of Molecular Pathology, The Institute of Cancer Research, London; Centre for Molecular Pathology, The Royal Marsden NHS Foundation Trust, London, UK.
| |
Collapse
|
13
|
Smyth EC, Nyamundanda G, Cunningham D, Fontana E, Ragulan C, Tan IB, Lin SJ, Wotherspoon A, Nankivell M, Fassan M, Lampis A, Hahne JC, Davies AR, Lagergren J, Gossage JA, Maisey N, Green M, Zylstra JL, Allum WH, Langley RE, Tan P, Valeri N, Sadanandam A. A seven-Gene Signature assay improves prognostic risk stratification of perioperative chemotherapy treated gastroesophageal cancer patients from the MAGIC trial. Ann Oncol 2018; 29:2356-2362. [PMID: 30481267 PMCID: PMC6311954 DOI: 10.1093/annonc/mdy407] [Citation(s) in RCA: 28] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022] Open
Abstract
Background Following neoadjuvant chemotherapy for operable gastroesophageal cancer, lymph node metastasis is the only validated prognostic variable; however, within lymph node groups there is still heterogeneity with risk of relapse. We hypothesized that gene profiles from neoadjuvant chemotherapy treated resection specimens from gastroesophageal cancer patients can be used to define prognostic risk groups to identify patients at risk for relapse. Patients and methods The Medical Research Council Adjuvant Gastric Infusional Chemotherapy (MAGIC) trial (n = 202 with high quality RNA) samples treated with perioperative chemotherapy were profiled for a custom gastric cancer gene panel using the NanoString platform. Genes associated with overall survival (OS) were identified using penalized and standard Cox regression, followed by generation of risk scores and development of a NanoString biomarker assay to stratify patients into risk groups associated with OS. An independent dataset served as a validation cohort. Results Regression and clustering analysis of MAGIC patients defined a seven-Gene Signature and two risk groups with different OS [hazard ratio (HR) 5.1; P < 0.0001]. The median OS of high- and low-risk groups were 10.2 [95% confidence interval (CI) of 6.5 and 13.2 months] and 80.9 months (CI: 43.0 months and not assessable), respectively. Risk groups were independently prognostic of lymph node metastasis by multivariate analysis (HR 3.6 in node positive group, P = 0.02; HR 3.6 in high-risk group, P = 0.0002), and not prognostic in surgery only patients (n = 118; log rank P = 0.2). A validation cohort independently confirmed these findings. Conclusions These results suggest that gene-based risk groups can independently predict prognosis in gastroesophageal cancer patients treated with neoadjuvant chemotherapy. This signature and associated assay may help risk stratify these patients for post-surgery chemotherapy in future perioperative chemotherapy-based clinical trials.
Collapse
Affiliation(s)
| | - G Nyamundanda
- Division of Molecular Pathology, Institute of Cancer Research, London, UK; Centre for Molecular Pathology, Royal Marsden Hospital, London, UK
| | - D Cunningham
- Royal Marsden Hospital, London, UK; Centre for Molecular Pathology, Royal Marsden Hospital, London, UK
| | - E Fontana
- Division of Molecular Pathology, Institute of Cancer Research, London, UK; Centre for Molecular Pathology, Royal Marsden Hospital, London, UK
| | - C Ragulan
- Division of Molecular Pathology, Institute of Cancer Research, London, UK; Centre for Molecular Pathology, Royal Marsden Hospital, London, UK
| | - I B Tan
- Medical Oncology, National Cancer Centre Singapore, Singapore
| | - S J Lin
- Bioinformatics Division, The Walter and Eliza Hall Institute of Medical Research, Victoria, Australia; Division of Research, Peter MacCallum Cancer Centre, University of Melbourne, Victoria, Australia
| | | | - M Nankivell
- Clinical Trials Unit, Medical Research Council, University College London, London, UK
| | - M Fassan
- Department of Pathology, University of Padua, Padua, Italy
| | - A Lampis
- Division of Molecular Pathology, Institute of Cancer Research, London, UK; Centre for Molecular Pathology, Royal Marsden Hospital, London, UK
| | - J C Hahne
- Division of Molecular Pathology, Institute of Cancer Research, London, UK; Centre for Molecular Pathology, Royal Marsden Hospital, London, UK
| | | | - J Lagergren
- Guys & St Thomas' Hospital, London, UK; Upper Gastrointestinal Surgery, Department of Molecular Medicine and Surgery, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden
| | | | - N Maisey
- Guys & St Thomas' Hospital, London, UK
| | - M Green
- Guys & St Thomas' Hospital, London, UK
| | - J L Zylstra
- Department of Pathology, University of Padua, Padua, Italy
| | | | - R E Langley
- Clinical Trials Unit, Medical Research Council, University College London, London, UK
| | - P Tan
- Cancer and Stem Cell Biology, Duke-NUS Medical School, Singapore
| | - N Valeri
- Royal Marsden Hospital, London, UK; Division of Molecular Pathology, Institute of Cancer Research, London, UK; Centre for Molecular Pathology, Royal Marsden Hospital, London, UK
| | - A Sadanandam
- Division of Molecular Pathology, Institute of Cancer Research, London, UK; Centre for Molecular Pathology, Royal Marsden Hospital, London, UK.
| |
Collapse
|
14
|
Tarazona Llavero N, Fontana E, Gambardella V, Gimeno-Valiente F, Castillo J, Calon A, Martínez-Ciarpaglini C, Peiró-Chova L, Huerta M, Zuñiga S, Rentero-Garrido P, Montón-Bueno J, Roda D, Roselló S, Bellosillo B, Vivancos A, Nyamundana G, Montagut C, Sadanandam A, Cervantes A. A multi-omic analysis for prospective patient stratification in localised colorectal cancer (CRC). Ann Oncol 2018. [DOI: 10.1093/annonc/mdy424.025] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
15
|
Dillon M, Bergerhoff K, Pedersen M, Whittock H, Patin E, Smith H, Paget J, Patel R, Bozhanova G, Foo S, Campbell J, Ragulan C, Fontana E, Wilkins A, Sadanandam A, Melcher A, McLaughlin M, Harrington K. ATR inhibition with radiation creates an inflammatory tumour microenvironment. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy303.019] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
16
|
Damavandi MD, Vlachogiannis G, Nyamundanda G, Lampis A, Hedayat S, Parkes H, Hahne J, Sadanandam A, Sansom O, Valeri N. PO-346 Defining microRNA mediated regulation of metabolic pathways involved in colon cancer progression (BST1-microRNA interactions). ESMO Open 2018. [DOI: 10.1136/esmoopen-2018-eacr25.858] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022] Open
|
17
|
Fontana E, Ragulan C, Eason K, Si-Lin K, Siew T, Nyamundanda G, Patil Y, Poudel P, Chau I, Tan I, Sadanandam A. Validated nCounter platform to stratify colorectal cancer (CRC) into Consensus Molecular Subtypes (CMS) and CRCassigner subtypes in Asian population. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx659.003] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
18
|
Smyth E, Nyamundanda G, Cunningham D, Tan I, Fontana E, Ragulan C, Okines A, Lin S, Wotherspoon A, Nankivell M, Peckitt C, Valeri N, Langley R, Tan P, Sadanandam A. Prognostic gene expression signature in chemotherapy treated patients from the MAGIC trial. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx660] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
19
|
Fontana E, Ragulan C, Cunningham D, Hulkki-Wilson S, Sclafani F, Nyamundanda G, Eason K, Begum R, Chong I, Peckitt C, Bali M, Oates J, Watkins D, Rao S, Hubank M, Wotherspoon A, Valeri N, Chau I, Starling N, Sadanandam A. Multiplatform assay to classify formalin-fixed paraffin-embedded (FFPE) colorectal cancer (CRC) samples into molecular subtypes with mutational profiles. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx393.097] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
20
|
Fontana E, Poudel P, Nyamundanda G, Patil Y, Ragulan C, Sadanandam A. Characterisation of heterogeneity in microsatellite instable (MSI) tumours associated with distinct cell types and immune phenotypes. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx363.024] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
21
|
Sadanandam A, Eason K, Fontana E, Nyamundanda G, Del Rio M, Si-Lin K, Siew T, Martineau P, Tan I, Ragulan C. Development and validation of multiplex biomarker assay to stratify colorectal cancer (CRC) patient samples into subtypes. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx393.088] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
22
|
Young K, Ragulan C, Nyamundanda G, Patil Y, Lawlor R, Cunningham D, Starling N, Scarpa A, Sadanandam A. Immune landscape of pancreatic neuroendocrine tumours (PanNETs). Ann Oncol 2017. [DOI: 10.1093/annonc/mdx368.001] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
23
|
Ragulan C, Poudel P, Young K, Nyamundanda G, Lawlor R, Scarpa A, Sadanandam A. Undiscovered immune heterogeneity in pancreatic adenocarcinoma (PDAC). Ann Oncol 2017. [DOI: 10.1093/annonc/mdx376.042] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
24
|
Homicsko K, Sadanandam A. New Molecular Classification of Colorectal Cancer. Ann Oncol 2014. [DOI: 10.1093/annonc/mdu296.1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
25
|
Dienstmann R, Guinney J, Delorenzi M, De Reynies A, Roepman P, Sadanandam A, Vermeulen L, Schlicker A, Missiaglia E, Soneson C, Marisa L, Homicsko K, Wang X, Simon I, Laurent-Puig P, Wessels L, Medema J, Kopetz S, Friend S, Tejpar S. Colorectal Cancer Subtyping Consortium (CRCSC) Identifies Consensus of Molecular Subtypes. Ann Oncol 2014. [DOI: 10.1093/annonc/mdu193.25] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
|
26
|
Sadanandam A, Sidhu SS, Wullschleger S, Singh S, Varney ML, Yang CS, Ashour AE, Batra SK, Singh RK. Secreted semaphorin 5A suppressed pancreatic tumour burden but increased metastasis and endothelial cell proliferation. Br J Cancer 2012; 107:501-7. [PMID: 22782341 PMCID: PMC3405228 DOI: 10.1038/bjc.2012.298] [Citation(s) in RCA: 41] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023] Open
Abstract
Background: Our earlier reports demonstrated that membrane-bound semaphorin 5A (SEMA5A) is expressed in aggressive pancreatic cancer cells and tumours, and promotes tumour growth and metastasis. In this study, we examine whether (1) pancreatic cancer cells secrete SEMA5A and (2) that secreted SEMA5A modulates certain phenotypes associated with tumour progression, angiogenesis and metastasis through various other molecular factors and signalling proteins. Methods and results: In this study, we show that human pancreatic cancer cell lines secrete the extracellular domain (ECD) of SEMA5A (SEMA5A-ECD) and overexpression of mouse Sema5A-ECD in Panc1 cells (not expressing SEMA5A; Panc1-Sema5A-ECD; control cells - Panc1-control) significantly increases their invasion in vitro via enhanced ERK phosphorylation. Interestingly, orthotopic injection of Panc1-Sema5A-ECD cells into athymic nude mice results in a lower primary tumour burden, but enhances the micrometastases to the liver as compared with Panc1-control cells. Furthermore, there is a significant increase in proliferation of endothelial cells treated with conditioned media (CM) from Panc1-Sema5A-ECD cells and a significant increase in microvessel density in Panc1-Sema5A-ECD orthotopic tumours compared with those from Panc1-control cells, suggesting that the increase in liver micrometastases is probably due to increased tumour angiogenesis. In addition, our data demonstrate that this increase in endothelial cell proliferation by Sema5A-ECD is mediated through the angiogenic molecules – interleukin-8 and vascular endothelial growth factor. Conclusion: Taken together, these results suggest that a bioactive, secreted form of Sema5A-ECD has an intriguing and potentially important role in its ability to enhance pancreatic tumour invasiveness, angiogenesis and micrometastases.
Collapse
Affiliation(s)
- A Sadanandam
- Department of Pathology and Microbiology, University of Nebraska Medical Center, 985900 Nebraska Medical Center, Omaha, NE 68198-5900, USA.
| | | | | | | | | | | | | | | | | |
Collapse
|
27
|
Radhika T, Mahendar P, Venkatesha A, Reddy A, Reddy YN, Sadanandam A, Christophe T. Hypoglycemic Activity of Red Kino Tree in Normal and Streptozotocin Induced Diabetic Rats. INT J PHARMACOL 2010. [DOI: 10.3923/ijp.2010.301.305] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
28
|
Rao AV, JayaSree T, Ramesh M, Pavan U, Sadanandam A. Nitrosomethylurea induced streptomycin resistance in Lycopersicon esculentum Mill. Indian J Exp Biol 2000; 38:617-20. [PMID: 11116537] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/18/2023]
Abstract
High frequency of streptomycin resistant variants of Lycopersicon esculentum were isolated on selective shoot regeneration medium supplemented with IAA (0.5 mg/L), zeatin (1.5 mg/L) and streptomycin sulphate (500 mg/L). Nonmutagenized (controls) and NMU treated cotyledons were placed on shoot regeneration medium supplemented with antibiotic streptomycin. Resistant shoots appeared at a high frequency in mutagenized cotyledons, whereas in controls morphogenesis was suppressed, accompanied by bleaching. Shoot regeneration occurred from the nodular tissues developed at the cut ends of cotyledons. Resistant shoots developed into complete plantlets on rooting medium containing selective concentration of antibiotic. Stability of streptomycin resistance was confirmed by leaf assay and reciprocal crosses between streptomycin-resistant and sensitive plants.
Collapse
Affiliation(s)
- A V Rao
- Plant Biotechnology Research Unit, Department of Botany, Kakatiya University, Warangal 506009, India
| | | | | | | | | |
Collapse
|
29
|
Rao AV, Farooqui MA, Sadanandam A. Induction of lincomycin and streptomycin resistance by nitrosomethylurea and ethyl methanesulphonate in Capsicum annuum L. Plant Cell Rep 1997; 16:865-868. [PMID: 30727594 DOI: 10.1007/s002990050335] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/09/2023]
Abstract
A high frequency of plastid-encoded antibiotic-resistant variants of Capsicum annuum were isolated on selective media following treatment by ethyl methanesulphonate (EMS) and nitrosomethylurea (NMU). Seeds and explants were mutagenized with 0.1% EMS and 5 mM NMU separately. Non-mutagenized cotyledons (controls), mutagenized cotyledons from EMS-treated seedlings and NMU-treated cotyledons were placed on regeneration medium supplemented with the antibiotics streptomycin or lincomycin. Resistant shoots appeared at a high frequency in mutagenized cotyledons, whereas in controls morphogenesis was suppressed, accompanied by bleaching. The stability of streptomycin and lincomycin resistance was confirmed by leaf assay. NMU-treated cotyledons gave a higher frequency of variants than cotyledons from EMS-treated seedlings. The mutagenic effect of EMS was more pronounced using whole seeds rather than cotyledons; in contrast, NMU was more effective in inducing variations in cotyledons than in seeds.
Collapse
Affiliation(s)
- A V Rao
- Plant Cell and Tissue Culture Laboratory, Department of Botany, Kakatiya University, Warangal-506 009, A. P., India Fax no.: +91-08712-78935, , , , , , IN
| | - M Ashfaq Farooqui
- Plant Cell and Tissue Culture Laboratory, Department of Botany, Kakatiya University, Warangal-506 009, A. P., India Fax no.: +91-08712-78935, , , , , , IN
| | - A Sadanandam
- Plant Cell and Tissue Culture Laboratory, Department of Botany, Kakatiya University, Warangal-506 009, A. P., India Fax no.: +91-08712-78935, , , , , , IN
| |
Collapse
|
30
|
Rao AV, Farooqui A, Sree TJ, Ramana RV, Sadanandam A. EMS-induced streptomycin resistance in Solanum melongena. Theor Appl Genet 1993; 87:527-530. [PMID: 24190326 DOI: 10.1007/bf00215099] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 04/01/1993] [Accepted: 05/03/1993] [Indexed: 06/02/2023]
Abstract
Streptomycin-resistant mutations were induced in Solanum melongena by exposing seeds to ethyl methane sulphonate (EMS). Seed mutagenesis resulted in a high frequency of chlorophyll-deficient mutations and a low frequency of resistant shoots, both of which retained their resistance on subsequent testing. Reciprocal crosses between streptomycin-resistant and -sensitive plants showed a non-Mendelian transmission of the resistance trait. Streptomycin resistance is the first selectable and maternally inherited organelle marker described in brinjal.
Collapse
Affiliation(s)
- A V Rao
- Plant Cell and Tissue Culture Laboratory, Department of Botany, Kakatiya University, 506009, Warangal, India
| | | | | | | | | |
Collapse
|
31
|
Ottesen EA, Vijayasekaran V, Kumaraswami V, Perumal Pillai SV, Sadanandam A, Frederick S, Prabhakar R, Tripathy SP. A controlled trial of ivermectin and diethylcarbamazine in lymphatic filariasis. N Engl J Med 1990; 322:1113-7. [PMID: 2181312 DOI: 10.1056/nejm199004193221604] [Citation(s) in RCA: 87] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/30/2022]
Abstract
Ivermectin is a new antifilarial drug that can be given in a single oral dose. To compare the efficacy and side effects of ivermectin with those of diethylcarbamazine, the standard antifilarial treatment, we conducted a randomized, double-blind trial in 40 South Indian men with lymphatic filariasis caused by Wuchereria bancrofti. Patients were randomly assigned to one of three treatments: a single low dose of ivermectin (mean [+/- SE], 21.3 +/- 0.7 micrograms per kilogram of body weight; n = 13) followed by placebo for 12 days; a single high dose of ivermectin (mean, 126.2 +/- 3.7 micrograms per kilogram; n = 13) followed by placebo for 12 days; or diethylcarbamazine for 13 days (6 mg per kilogram per day for 12 days preceded by 3 mg per kilogram for 1 day; n = 14). Eleven patients were initially assigned to receive placebo and after five days were reassigned to one of the three treatment groups. At day 12 there was complete clearance of microfilariae from the blood in all 26 men who took ivermectin and in 11 of the 14 men who took diethylcarbamazine. At six months the numbers of detectable microfilariae (as a percentage of the pretreatment values) were 18.3 percent after low-dose ivermectin and 19.5 percent after high-dose ivermectin, as compared with 6.0 percent after diethylcarbamazine (P less than 0.05). The side effects were confined to the first five days and were similar in the three treatment groups. We conclude that in lymphatic filariasis, the clinical response to a single dose of ivermectin compares favorably with that after the standard 12-day course of diethylcarbamazine. Given the practical advantages of single-dose administration, ivermectin should become a useful medication for the control of bancroftian filariasis.
Collapse
Affiliation(s)
- E A Ottesen
- Laboratory of Parasitic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Md. 20892
| | | | | | | | | | | | | | | |
Collapse
|
32
|
Affiliation(s)
- N. Devadas
- Cytogenetics Laboratory, Botany Department, Kakatiya University
| | - A. Sadanandam
- Cytogenetics Laboratory, Botany Department, Kakatiya University
| | - R. Kishan Rao
- Cytogenetics Laboratory, Botany Department, Kakatiya University
| | - K. Subhash
- Cytogenetics Laboratory, Botany Department, Kakatiya University
| |
Collapse
|
33
|
|
34
|
Affiliation(s)
- A. Sadanandam
- Cytogenetics Laboratory, Botany Department, Kakatiya University
| | - K. Subhash
- Cytogenetics Laboratory, Botany Department, Kakatiya University
| |
Collapse
|